论文部分内容阅读
目的初步探讨前列腺特异性膜抗原(PSMA)及其变异体(PSMA5)DNA检测在前列腺癌诊断中的临床意义。方法用自建的荧光定量逆转录聚合酶链反应(FQ-RT-PCR)检测方法检测前列腺增生及前列腺癌患者及正常对照组外周血单个核细胞和血浆中PSMA和PSMA5DNA的含量。结果在前列腺癌及前列腺增生患者外周血单个核细胞中PSMADNA含量及水平明显高于正常对照组。而PSMA5DNA含量在前列腺癌患者的外周血单个核细胞中明显高于PSMADNA。结论 PSMA及PSMA5DNA在外周血单个核细胞中的差异提示了作为前列腺癌的肿瘤标志物,PSMA5更具有肿瘤特异性,对其DNA的检测为前列腺肿瘤标志物的研究指明了一条新的道路。
Objective To investigate the clinical significance of prostate specific membrane antigen (PSMA) and its variant (PSMA5) DNA in the diagnosis of prostate cancer. Methods The levels of PSMA and PSMA5 DNA in peripheral blood mononuclear cells and plasma from patients with benign prostatic hyperplasia and prostate cancer and normal controls were detected by self-built fluorescent quantitative reverse transcription-polymerase chain reaction (FQ-RT-PCR). Results The levels and levels of PSMADNA in peripheral blood mononuclear cells of patients with prostate cancer and benign prostatic hyperplasia were significantly higher than those of the normal control group. The PSMA5DNA content in peripheral blood mononuclear cells of patients with prostate cancer was significantly higher than PSMADNA. Conclusions The differences of PSMA and PSMA5DNA in peripheral blood mononuclear cells suggest that PSMA5 is more tumor-specific as a tumor marker for prostate cancer. It has indicated a new path for its DNA detection as a marker of prostate cancer.